Skip to content
value.today

Viewpoint Molecular Targeting, Inc.

Formerly Viewpoint Molecular Targeting, LLC

Total raised
$14 M
1 round on record
Latest round
$14 M
Nov 2020
First round on record
Nov 2020
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Viewpoint Molecular Targeting, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2020$14 MNo. 1$10 to $50 million

Viewpoint Molecular Targeting, Inc.: Raise no. 1, Nov 2020

Investors in this round

29 investors had bought by the notice of Jan 15, 2021: 29 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$14 M of $16 M offered; $2 M still to sell
Smallest investment taken
$25,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,006,931
Finders' fees
none
Paid to its own people
$500,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Frances Johnson · Executive Officer, Director
  • Heyward Coleman · Executive Officer, Director
  • Michael Schultz · Executive Officer, Director
  • Cameron Gray · Director
  • Curtis Nelson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • National Securities Corporation (CRD 7569) · Boca Raton, FloridaSold in CA, DC, FL, IA, IL, MD, NE, SC, TX

Remarks in the notice

  • On fees: “Cash sales compensation of $956,930.92 and reimbursed expenses of $50,000. Additionally, warrants to purchase 1,070,443 shares of common stock of the issuer at the per share offering price were issued to the broker and its designees.”
  • On the amounts: “Total offering amount is subject to increase by the issuer. Total offering amount and total amount sold include conversion of outstanding debt in the aggregate amount of $847,498.”
  • On the use of proceeds: “Compensation to executive officers in the ordinary course pursuant to their Board-approved existing employment agreements.”

Signed by Frances L. Johnson, Ceo. Source: SEC Form D and 2 amendments, newest notice filed Jan 15, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Viewpoint Molecular Targeting, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2021).

    SEC Form D · Jan 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jan 2021

That is all the official record says: Viewpoint Molecular Targeting, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Viewpoint Molecular Targeting, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 29 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Viewpoint Molecular Targeting, Inc.
NameRoleNamed in
Frances JohnsonExecutive officerJan 2021
Heyward ColemanExecutive officerJan 2021
Michael SchultzExecutive officerJan 2021
Cameron GrayDirectorJan 2021
Curtis NelsonDirectorJan 2021
Frances JohnsonDirectorJan 2021
Heyward ColemanDirectorJan 2021
Michael SchultzDirectorJan 2021